REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

Yesterday 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260410:nRSJ0486Aa&default-theme=true

RNS Number : 0486A  GSK PLC  10 April 2026

 

GSK plc (the 'Company')

Transaction notification

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Luke Miels
 b)  Position/status                          Chief Executive Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              2

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 1.  Details of PDMR/person closely associated with them ('PCA')

 a)  Name                                     Lynn Baxter
 b)  Position/status                          President, Europe
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              32

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Diana Conrad
 b)  Position/status                          Chief People Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              5

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     James Ford
 b)  Position/status                          SVP and Group General Counsel, Legal and Compliance
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              10

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     David Redfern
 b)  Position/status                          President Corporate Development
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              67

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Regis Simard
 b)  Position/status                          President, Global Supply Chain
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              27

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Philip Thomson
 b)  Position/status                          President, Global Affairs
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              44

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Deborah Waterhouse
 b)  Position/status                          CEO, ViiV Healthcare and President, Global Health, GSK
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              56

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Victoria Whyte
 b)  Position/status                          SVP & Company Secretary
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              52

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Neil Falkingham
 b)  Position/status                          PCA of Lynn Baxter (President, Europe)
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63

 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026 on shares held through the Company's Share
                                              Reward Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.3387              54

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Victoria Whyte
 b)  Position/status                          SVP & Company Secretary
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026.
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.5039              208

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Iain Whyte
 b)  Position/status                          PCA of Victoria Whyte (SVP & Company Secretary)
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                Acquisition of Ordinary Shares following the re-investment of dividends paid
                                              to shareholders on 9 April 2026.
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £21.5039              1,006

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-04-09
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com) .

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSFSFDSEMSEIL



            Copyright 2019 Regulatory News Service, all rights reserved